BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMLIBRA (emicizumab) is a monoclonal antibody (mAb) bispecific bridging Factor IXa and Factor X to restore hemostatic balance in hemophilia patients. It is indicated for hemophilia A, Factor VIII deficiency, von Willebrand disease Type 3, hemophilic pseudotumor, and acquired hemophilia A. The drug provides subcutaneous prophylaxis, reducing breakthrough bleeding events.
Peak
HEMLIBRA is at peak commercial maturity with 11 linked career roles, indicating stable and established market presence supporting substantial medical and commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Started Jun 2026
5 enrolled
Hemophilia A
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Started Apr 2026
360 enrolled
Hemophilia A
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Started Jun 2025
75 enrolled
Von Willebrand Disease, Type 3
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Started May 2025
15 enrolled
Severe Hemophilia A
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
Started Aug 2024
71 enrolled
Hemophilia A
Worked on HEMLIBRA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.